Mmbg Investment Advisors CO. Reduces Stock Holdings in Danaher Corporation (NYSE:DHR)

Mmbg Investment Advisors CO. reduced its stake in Danaher Corporation (NYSE:DHR - Free Report) by 16.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,005 shares of the conglomerate's stock after selling 4,380 shares during the period. Mmbg Investment Advisors CO.'s holdings in Danaher were worth $4,723,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. FAS Wealth Partners Inc. increased its stake in Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Danaher by 3.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock worth $933,524,000 after acquiring an additional 135,047 shares during the last quarter. Camden National Bank grew its position in shares of Danaher by 285.0% during the fourth quarter. Camden National Bank now owns 7,227 shares of the conglomerate's stock worth $1,659,000 after acquiring an additional 5,350 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock worth $1,303,163,000 after acquiring an additional 579,046 shares during the last quarter. Finally, Terra Alpha Investments LLC purchased a new position in shares of Danaher during the fourth quarter worth approximately $3,068,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Leerink Partners raised their target price on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Wells Fargo & Company lowered their target price on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Jefferies Financial Group lowered their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Royal Bank Of Canada restated an "outperform" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Finally, Citigroup reaffirmed a "buy" rating on shares of Danaher in a report on Monday, April 7th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $248.61.

Insider Transactions at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Danaher Price Performance

Danaher stock opened at $198.20 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The business has a fifty day moving average of $194.84 and a two-hundred day moving average of $208.33. The company has a market cap of $141.84 billion, a P/E ratio of 38.48, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.